Literature DB >> 16709174

Cytokines and proteoglycans: an introductory overview.

B Mulloy1, C C Rider.   

Abstract

The defining characteristic of the glycoproteins known as proteoglycans is the presence of O-linked acidic polysaccharides known as GAGs (glycosaminoglycans). The backbone of these linear polysaccharides is a repeating disaccharide, comprising N-acetyl hexosamine alternating with beta-D-glucuronic acid, alpha-L-iduronic acid, or galactose. For some GAGs, partial deacetylation, epimerization of glucuronic acid, and substitution with N- and O-sulphates result in highly complex, heterogeneous structures. The interactions with proteins through which GAGs exert their biological effects depend on the resulting sequences. Some proteins, for example antithrombin, have highly specific sequence requirements for their GAG ligand [in this case heparin or HS (heparan sulphate)]; others, for example the fibroblast growth factors, are less demanding. GAGs, in particular HS, play a role as co-receptors for some cytokines. In addition, HS is thought to be important for the localization of cytokines, acting both as a tissue store and as a mediator of morphogen gradient formation in development. The structural determinants of GAG-cytokine interactions are therefore clearly important to understanding the biology of development, wound healing and the immune system. No single paradigm has been identified for such interactions, and the search for general principles underlying involvement of GAGs in cytokine function is at an early stage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709174     DOI: 10.1042/BST0340409

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  23 in total

Review 1.  Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection.

Authors:  Sean Gill; Thomas N Wight; Charles W Frevert
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

Review 2.  Biochemical and biomechanical characterization of porcine small intestinal submucosa (SIS): a mini review.

Authors:  Lei Shi; Vincent Ronfard
Journal:  Int J Burns Trauma       Date:  2013-11-01

3.  Differential expression of matrix metalloproteinases in the serum of patients with mucopolysaccharidoses.

Authors:  Spyros P Batzios; Dimitrios I Zafeiriou; Euthymia Vargiami; George Karakiulakis; Eleni Papakonstantinou
Journal:  JIMD Rep       Date:  2011-09-22

4.  In vitro and in vivo affinity microdialysis sampling of cytokines using heparin-immobilized microspheres.

Authors:  Jia Duo; Julie A Stenken
Journal:  Anal Bioanal Chem       Date:  2010-10-30       Impact factor: 4.142

5.  Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.

Authors:  Rosendo Luria-Pérez; Pierre V Candelaria; Tracy R Daniels-Wells; José A Rodríguez; Gustavo Helguera; Manuel L Penichet
Journal:  Cytokine       Date:  2019-05-20       Impact factor: 3.861

6.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Michela Asperti; Annamaria Naggi; Natascia Campostrini; Domenico Girelli; Michela Corbella; Marina Benzi; Celine Besson-Fournier; Helene Coppin; Federica Maccarinelli; Dario Finazzi; Paolo Arosio
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

7.  HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.

Authors:  Ashwani Khurana; Peng Liu; Pasquale Mellone; Laura Lorenzon; Bruno Vincenzi; Kaustubh Datta; Bo Yang; Robert J Linhardt; Wilma Lingle; Jeremy Chien; Alfonso Baldi; Viji Shridhar
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

8.  Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.

Authors:  Claire L Cole; Steen U Hansen; Marek Baráth; Graham Rushton; John M Gardiner; Egle Avizienyte; Gordon C Jayson
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

Review 9.  Therapeutically targeting protein-glycan interactions.

Authors:  A Rek; E Krenn; A J Kungl
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

10.  Role of 6-O-sulfated heparan sulfate in chronic renal fibrosis.

Authors:  Abd A Alhasan; Julia Spielhofer; Marion Kusche-Gullberg; John A Kirby; Simi Ali
Journal:  J Biol Chem       Date:  2014-05-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.